EssilorLuxottica to acquire Signifeye

Published on December 17, 2025
The agreement with the Belgian ophthalmology provider follows the completion of the acquisition of Optegra earlier this year
Continue reading on website
Other news

Dompé enrolls first patients in phase 3 trial of Isocyclosporin for atopic keratoconjunctivitis | Optometry Times - Clinical News

December 16, 2025
Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Optometry Times - Clinical News

December 17, 2025
K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.